Galangin as an inflammatory response modulator: An updated overview and therapeutic potential

Riya Thapa, Obaid Afzal, Abdulmalik Saleh Altamimi, Ahsas Goyal, Waleed Hassan Almalki, Sami I. Alzarea, Imran Kazmi, Vikash Jakhmola, Sachin Kumar Singh, Kamal Dua, Ritu Gilhotra, Gaurav Gupta

Research output: Contribution to journalReview articlepeer-review

105 Scopus citations

Abstract

Numerous chronic diseases, such as cancer, diabetes, rheumatoid arthritis, cardiovascular disease, and gastrointestinal disorders, all have an inflammation-based etiology. In cellular and animal models of inflammation, flavonols were used to show potent anti-inflammatory activity. The flavonols enhanced the synthesis of the anti-inflammatory cytokines transforming growth factor and interleukin-10 (IL-10) and reduced the synthesis of the prostaglandins IL-6, tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2), IL-1. Galangin (GAL), a natural flavonol, has a strong ability to control apoptosis and inflammation. GAL was discovered to suppress extracellular signal-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)p65 phosphorylation, which results in anti-inflammatory actions. Arthritis, inflammatory bronchitis, stroke, and cognitive dysfunction have all been treated with GAL. The current review aimed to demonstrate the anti-inflammatory properties of GAL and their protective effects in treating various chronic illnesses, including those of the heart, brain, skin, lungs, liver, and inflammatory bowel diseases.

Original languageEnglish
Article number110482
JournalChemico-Biological Interactions
Volume378
DOIs
StatePublished - 1 Jun 2023

Keywords

  • Cardiac inflammation
  • Flavonoid
  • Galangin
  • Nephritis
  • Neuroinflammation

Fingerprint

Dive into the research topics of 'Galangin as an inflammatory response modulator: An updated overview and therapeutic potential'. Together they form a unique fingerprint.

Cite this